Zymeworks(US:ZYME) ZACKSยท2024-08-01 23:11Group 1 - Zymeworks Inc. reported a quarterly loss of $0.26 per share, slightly better than the Zacks Consensus Estimate of a loss of $0.27, and an improvement from a loss of $0.76 per share a year ago, resulting in an earnings surprise of 3.70% [1] - The company posted revenues of $19.24 million for the quarter ended June 2024, missing the Zacks Consensus Estimate by 16.93%, but showing significant growth from $7 million in the same quarter last year [2] - Over the last four quarters, Zymeworks has surpassed consensus EPS estimates three times, but has only topped consensus revenue estimates once [2] Group 2 - The stock has added about 0.7% since the beginning of the year, underperforming compared to the S&P 500's gain of 15.8% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.46 on revenues of $12.09 million, and for the current fiscal year, it is -$1.24 on revenues of $92.54 million [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is currently in the top 35% of over 250 Zacks industries, indicating a favorable outlook for the industry [8]